Novartis Reaches $185M Deal Over Off-Label Claims

Law360, New York (January 26, 2010, 7:08 PM EST) -- Novartis AG announced Tuesday that it will pay a $185 million fine to resolve criminal allegations that the drugmaker engaged in off-label marketing and promotion of epilepsy drug Trileptal.

In a filing with the U.S. Securities and Exchange Commission, Novartis said the U.S. Attorney's Office for the Eastern District of Pennsylvania had served one of its subsidiaries with an administrative subpoena in 2005, and that the subsidiary recently entered into a plea agreement to resolve the allegations.

Pursuant to the plea agreement, which is still subject...
To view the full article, register now.